NSE: KIMSHealthcareLarge Cap

Krishna Institute of Medical Sciences Ltd.

ISIN: INE967H01025 • Market Cap: ₹33,122 Cr

5-Pillar Score
54/100
Moderate / Average
P/E Ratio162.12
ROCE8.7%
ROE10.7%
Debt to Equity1.44
3Y Sales CAGR19.0%
Promoter Holding32.5%
Detailed Quantitative Breakdown

The 5-Pillar Quality Audit for Krishna Institute of Medical Sciences Ltd.

Evaluated across Profitability, Financial Health, Historical Compounding, Valuation Safety, and Ownership Governance:

1. Profitability & Capital Efficiency

Weight: 25%
62/ 100

Measures operating margins (19.8%), Return on Capital Employed (8.7%), and equity compounding (10.7%).

2. Financial Health & Solvency

Weight: 25%
56/ 100

Debt-to-Equity is 1.44 with comfortable interest coverage and clean working capital.

3. Growth & Compounding Track Record

Weight: 20%
50/ 100

Historical 3Y Sales CAGR (19.0%) and 3Y PAT CAGR (-14.9%).

4. Valuation Multiple & Margin of Safety

Weight: 15%
25/ 100

Trades at P/E of 162.12 vs PEG of 3.95 and Dividend Yield of —.

5. Ownership Quality & Governance

Weight: 15%
72/ 100

Promoter holding stands at 32.5%, backed by 49.1% institutional ownership.

Key Fundamental Strengths

Strong Topline Expansion (3Y Sales CAGR: 19.0%)

Revenue has expanded at 19.0% CAGR over 3 years, signaling industry market-share gains.

Deep Institutional Sponsorship (49.1%)

Mutual funds, domestic DIIs, and foreign FIIs hold 49.1%, providing strong governance scrutiny.

Areas to Watch & Potential Risks

Subdued Capital Efficiency (ROCE: 8.7%)

A sub-12% ROCE suggests return on capital barely exceeds the company's weighted average cost of capital (WACC).

Elevated Financial Gearing (D/E: 1.44)

Debt-to-Equity exceeds 0.9x, meaning substantial operating earnings are absorbed by mandatory interest coverage.

Priced for Perfection (P/E: 162.12)

A steep valuation multiple of 162.12 leaves little margin for safety against quarterly earnings misses.

Institutional Strategy Filters

Quantitative Strategy Eligibility

Checking KIMS against established Indian wealth creation frameworks:

Fails Screen

Coffee Can Investing Framework

Fails 10%+ revenue growth or 15%+ minimum capital return benchmark over historical periods.

Borderline

Quality Factor Screener (High RoIC + Low Debt)

Scorecard of 54/100 or leverage profile sits below strict quality index hurdles.

Watchlist

GARP / Value-Growth Blend

Valuation multiple or return metrics require further cyclical pullback.

Industry Benchmark

Healthcare Sector Peer Comparison

Compare KIMS directly against top industry peers by market capitalization:

Company5-Pillar ScoreMarket CapP/EROCED/EScorecard
Krishna Institute of Medical Sciences Ltd. (KIMS)Current54/100₹33,122 Cr162.128.7%1.44—
Sun Pharmaceutical Industries Ltd. (SUNPHARMA)77/100₹4.55 Lakh Cr37.6520.4%0.05View
Divi's Laboratories Ltd. (DIVISLAB)73/100₹2.26 Lakh Cr77.3719.4%0.00View
Torrent Pharmaceuticals Ltd. (TORNTPHARM)64/100₹1.91 Lakh Cr87.439.5%1.76View
Apollo Hospitals Enterprise Ltd. (APOLLOHOSP)70/100₹1.27 Lakh Cr60.5519.1%0.62View
Cipla Ltd. (CIPLA)63/100₹1.14 Lakh Cr33.9416.1%0.01View

Frequently Asked Questions: Krishna Institute of Medical Sciences Ltd.

Q:What is the 5-Pillar Fundamental Score for Krishna Institute of Medical Sciences Ltd. (KIMS)?

Krishna Institute of Medical Sciences Ltd. has a RupeeTools Fundamental Score of 54/100, placing it in the 'Moderate / Average' category. Its pillar scores are: Profitability (62/100), Financial Health (56/100), Growth (50/100), Valuation (25/100), and Ownership Quality (72/100).

Q:Is KIMS fundamentally strong for long-term investment?

KIMS currently holds a moderate quality rating of 54/100. While it operates in the Healthcare sector, investors should monitor its debt health before initiating long-term positions.

Q:Does KIMS pass the Coffee Can Investing filter?

No. KIMS does not currently meet the strict 15% ROCE and 10% sustained topline compounding threshold mandated by the Coffee Can investing framework.

Q:How does KIMS compare against other Healthcare peers?

Within India's Healthcare sector, KIMS trades at a P/E of 162.12 and generates an ROCE of 8.7%. Compare its 5-Pillar score of 54/100 against top sector peers like Sun Pharmaceutical Industries Ltd. (77/100), Divi's Laboratories Ltd. (73/100).

Regulatory & SEBI Research Analyst Compliance Disclaimer:

This 5-pillar fundamental score is an automated quantitative health check generated purely from historical public financial statements, corporate filings, and exchange disclosures for educational and informational purposes only. It does NOT constitute investment advice, a stock recommendation, or a solicitation to buy or sell securities. RupeeTools is not a SEBI-registered Research Analyst. Please consult a SEBI-registered financial advisor before making investment decisions.